Literature DB >> 30029835

Risk factors of haemoglobinuria after microwave ablation of liver tumours.

D Li1, J Yu2, Z Han2, Z Cheng2, F Liu2, J Dou2, P Liang3.   

Abstract

AIM: To explore the risk factors predicting haemoglobinuria after ultrasound-guided percutaneous microwave ablation (MWA) of liver tumours and discuss the treatments and outcomes.
MATERIALS AND METHODS: The present study comprised 2,829 patients admitted for liver tumours treated with MWA from Jan 2011 to April 2017. Ethics committee approval was waived and informed consent for treatment procedures were obtained from the patients. Haemoglobinuria after MWA was found in 149 patients. The influence of 19 risk factors was assessed. Binary logistic regression and receiver operating characteristic (ROC) curve analysis were used for statistical analysis. The treatments and outcomes of patients with haemoglobinuria were summarised.
RESULTS: By univariate analysis, histopathology, liver cirrhosis, MWA volume, MWA energy, and MWA duration were significant risk factors. By multivariate analysis and ROC curve, MWA energy, duration, and volume were identified as predictors of haemoglobinuria after MWA. Drug treatments including kidney protection, adequate hydration, alkalisation of urine, and diuresis were administrated to the patients with haemoglobinuria. One patient progressed to acute kidney injury (AKI) while others had good clinical outcomes.
CONCLUSION: Haemoglobinuria is a controllable side effect after MWA of liver tumours, which is related to high MWA energy, long MWA duration, and great MWA volume. It usually caused few side effects on renal function with correct treatment.
Copyright © 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30029835     DOI: 10.1016/j.crad.2018.06.011

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  2 in total

Review 1.  Current concepts in ablative procedures for primary benign liver lesions: a step forward to minimize the invasiveness of treatment when deemed necessary.

Authors:  Aldo Carnevale; Fabio Pellegrino; Alberto Cossu; Anna Maria Ierardi; Gian Carlo Parenti; Gianpaolo Carrafiello; Melchiore Giganti
Journal:  Med Oncol       Date:  2020-03-19       Impact factor: 3.064

2.  New approach for hepatocellular carcinoma treatment.

Authors:  Daniela Tabacelia; Cezar Stroescu; Radu Dumitru; Raluca Roxana Grigorescu; Alexandru Martiniuc; Ioana Alexandra Husar-Sburlan; Narcis Copca
Journal:  J Med Life       Date:  2022-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.